Balaxi Pharmaceuticals opened higher at ₹22.58, compared with its previous close of ₹22.36. During today's session, the stock has traded between ₹21.50 and ₹22.58, with an average traded price of ₹21.94. It is currently showing a downward intraday trend.
An investment of ₹10,000 made 5 years ago in Balaxi Pharmaceuticals is now worth
₹ 1,800.00
resulting in a loss of
₹ 8,200.00 (82.00%)
Note: Past profits do not guarantee future returns.
No analyst rating data available.
Today's Change
-0.17 (-0.76%)
Day High
₹22.58
Day Low
₹21.50
Day Open
₹22.58
Prev Close
₹22.36
Volume
26,229
Value Traded
₹0.06 Cr
1W Return
-2.55%
1M Return
-5.13%
3M Return
-8.19%
6M Return
-6.73%
1Y Return
-48.95%
Market Cap (₹ Cr.)
123
PE Ratio
50.80
PB Ratio
0.50
Dividend Yield
2.24%
ROE
0.57%
ROCE
3.35%
Book Value (₹)
45.12
Face Value (₹)
2.00
EPS (TTM)
0.24
Industry PE
-
Beta
-
Debt to Equity
-
1 Week
-2.55%
6 Week
-
1 Month
-5.13%
3 Month
-8.19%
9 Month
-11.63%
Balaxi Pharmaceuticals reports NIL physical share transfers in May 2026
Balaxi Pharmaceuticals filed a report with the NSE stating that no requests were received, processed, approved, or rejected for the re-lodgement of physical share transfers in May 2026. The filing complies with a SEBI circular issued in January 2026. The Registrar and Share Transfer Agent, Aarthi Consultants Private Limited, confirmed the NIL status.
4mo agoBalaxi FY26 net profit falls 94% to ₹1.42 crore
Balaxi Pharmaceuticals reported a 94.3% decline in FY26 net profit to ₹1.42 crore, driven by a 7.7% drop in revenue to ₹270.17 crore and a 66.1% fall in EBITDA to ₹11.35 crore. The company cited extended working capital cycles in Angola but noted growth in Latin America. It commissioned a new formulation facility in Hyderabad and is discontinuing its Building Hardware business.
4mo agoBalaxi Pharmaceuticals Submits RTA Report on Physical Share Transfer Re-Lodgements for April 2026
Balaxi Pharmaceuticals Limited submitted its RTA report for April 2026 to the National Stock Exchange of India Limited, as required under SEBI Circular No. HO/38/13/11(2)2026-MIRSD-POD/I/3750/2026 dated 30th January, 2026. The report, prepared by M/s. Aarthi Consultants Private Limited, confirmed that no re-lodgement requests for physical share transfers were received, processed, approved, or rejected during the month. The filing was made on 12th May, 2026, and signed by Company Secretary and Compliance Officer Aman Purohit.
5mo agoBalaxi Pharmaceuticals Soars 22% Amid Major Stake Transfers
Balaxi Pharmaceuticals' stock price surged over 22% in two days following significant ownership changes. Ebisu Global Opportunities Fund and Unico Global Opportunities Fund each acquired approximately 8% stake at ₹53 per share. Simultaneously, MGC Fund Limited and Elala India Opportunities Fund divested their 8% stakes at the same price. The consistent transaction price suggests a mutually agreed valuation. The market responded positively to these bulk deals, reflecting increased investor interest in the company's future prospects.
19mo ago| Stock | LTP | Change % | Market Cap (Cr.) | PE | 1Y Return |
|---|---|---|---|---|---|
| ₹1,770.70 | +0.61% | ₹4,24,850.24 | 34.83 | +5.97% | |
| ₹9,285.00 | -1.50% | ₹2,46,487.58 | 85.12 | +43.41% | |
| ₹4,642.90 | -0.84% | ₹1,76,600.99 | 82.55 | +31.42% | |
| ₹1,132.50 | -0.17% | ₹1,12,967.31 | 24.74 | +14.00% | |
| ₹2,059.40 | -0.47% | ₹1,11,271.90 | 102.63 | +134.89% | |
| ₹1,329.60 | +1.40% | ₹1,07,412.86 | 31.62 | -14.87% | |
| ₹1,240.00 | +0.86% | ₹1,03,500.36 | 32.26 | -1.93% | |
| ₹2,372.00 | -1.17% | ₹97,974.30 | 47.92 | -3.57% | |
| ₹1,684.60 | -1.31% | ₹96,928.16 | 26.40 | +49.04% | |
| ₹1,953.60 | +0.96% | ₹89,336.17 | 16.03 | -0.29% | |
| ₹2,265.30 | -0.78% | ₹63,932.35 | 35.82 | +16.81% | |
| ₹5,250.00 | +0.86% | ₹62,771.63 | 28.34 | -3.75% |
An investment of ₹10,000 made 5 years ago in Balaxi Pharmaceuticals is now worth
₹ 1,800.00
resulting in a loss of
₹ 8,200.00 (82.00%)
Note: Past profits do not guarantee future returns.
